Syndax Pharmaceuticals, Inc. entered into subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031. The company expects net proceeds of approximately $243 million to be used for general corporate purposes, including research and development and commercialization. The notes feature an initial conversion price of approximately $24.76 per share.
